Deleted Tweets From Scott Gottlieb, R-D.C.

#FDA is concerned about risks associated with Kratom, and those self medicating with products that are opioids and haven’t been properly evaluated for safety and efficacy. Help is available. We’re committed to addressing needs of patients with chronic pain https://t.co/ntfmZ3YmzL

If we can harmonize global standards for generic drug regulatory submissions it can lead to more opportunity for global filings that increase access, competition. An end goal? A common application process that could enable multi-market approvals. https://t.co/yoOraEVm3B

The Quick Review pilot will not change our statutory or data requirements, but we expect it’ll reduce certain application review times as much as 30 percent, by allowing the #FDA to receive and evaluate information much more efficiently. https://t.co/1FlD08IK3K

RT @FDA_ORA: If a product that claims to “lower your blood sugar naturally” or be a “natural diabetes cure” sounds too good to b… https://t.co/qTeURa4fOw

RT @FDA_ORA: If a #hurricane or #flood is heading your way, the best thing you can do for your pets is to plan ahead so you are… https://t.co/UmORxsEmGq

#FDA is advancing new policies to finalize guidance on declaring added sugars on pure maple syrup and honey. We’ve taken stakeholder concerns into view and revised our approach. We’re committed to the effective adoption of the new Nutrition Facts Label: https://t.co/8lIw6pOq9I

#FDA is committed to effective implementation of the new Nutrition Facts Label — to make sure consumers receive the valuable information they need to inform their dietary choices while we make certain the new label can be efficiently adopted. https://t.co/vLXT1SOXDo

RT @SquawkCNBC: TUNE IN: Dr. Scott Gottlieb @SGottliebFDA, FDA Commissioner @ 7:15am ET today! https://t.co/cR8hyXZwbJ

RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA on new steps to help ensure the quality of and preserve access to com… https://t.co/tz5iQszMlN

RT @FDAfood: The FDA has completed its investigation into a multi-state outbreak of #cyclosporiasis illnesses associated with De… https://t.co/EMKaPwaDP5

My statement on the new steps #FDA is taking to promote access to safe compounded drugs and continue implementation of #DQSA. https://t.co/WmCojrvrkG

The states can play a vital role in reducing the risks associated with compounded drugs, while ensuring appropriate access. In furthering this important partnership and our shared goals, today we've issued a revised draft MOU between #FDA and the states https://t.co/OlSeeA7gor

RT @FDATobacco: The “Tips for Retailers” video has important info on FDA programs and technologies that can assist retailers in pre… https://t.co/K501hom4U3

The revised draft MOU addresses patient access concerns, while retaining critical safety provisions. It is an important step to increase our collaboration with the states to maximize resources and our collective public health impact. https://t.co/OlSeeA7gor

The MOU is a significant milestone in #FDA’s implementation of DQSA. Looking ahead we'll take several more actions on compounding in coming months to promotes safe, appropriate practices https://t.co/OlSeeA7gor I’ll share more on compounding this weekend in #FDA #SUNDAYTWEETORIAL

RT @coukell: Excited that @SGottliebFDA and senior @US_FDA officials will be @pewtrusts next Friday to talk about future efforts… https://t.co/X9W5xm6HjK

RT @FDAOMH: Nicotine, the highly addictive drug in tobacco, keeps people smoking even when they want to quit. During… https://t.co/OTHrFkcUkg

RT @FDACosmetics: DYK The term "cosmeceutical" has no meaning under the law. Don't be confused by cosmetics labeling, find out more… https://t.co/IvPGja6NBj

My recent statement on #FDA’s comprehensive campaign to confront the crisis of opioid abuse and misuse; and some of the new steps that the agency will be taking this fall: https://t.co/v50AHA2yEY

RT @FDASpox: Today, @SGottliebFDA issued a statement on new steps to help ensure the quality of and preserve access to compounde… https://t.co/2qTqGksG4V

#FDA is concerned about risks associated with Kratom, and those self medicating with products that are opioids and haven’t been properly evaluated for safety and efficacy. Help is available. We’re committed to addressing needs of patients with chronic pain https://t.co/ntfmZ3YmzL

If we can harmonize global standards for generic drug regulatory submissions it can lead to more opportunity for global filings that increase access, competition. An end goal? A common application process that could enable multi-market approvals. https://t.co/yoOraEVm3B

The Quick Review pilot will not change our statutory or data requirements, but we expect it’ll reduce certain application review times as much as 30 percent, by allowing the #FDA to receive and evaluate information much more efficiently. https://t.co/1FlD08IK3K

RT @FDA_ORA: If a product that claims to “lower your blood sugar naturally” or be a “natural diabetes cure” sounds too good to b… https://t.co/qTeURa4fOw

RT @FDA_ORA: If a #hurricane or #flood is heading your way, the best thing you can do for your pets is to plan ahead so you are… https://t.co/UmORxsEmGq

#FDA is advancing new policies to finalize guidance on declaring added sugars on pure maple syrup and honey. We’ve taken stakeholder concerns into view and revised our approach. We’re committed to the effective adoption of the new Nutrition Facts Label: https://t.co/8lIw6pOq9I

#FDA is committed to effective implementation of the new Nutrition Facts Label — to make sure consumers receive the valuable information they need to inform their dietary choices while we make certain the new label can be efficiently adopted. https://t.co/vLXT1SOXDo

RT @SquawkCNBC: TUNE IN: Dr. Scott Gottlieb @SGottliebFDA, FDA Commissioner @ 7:15am ET today! https://t.co/cR8hyXZwbJ

RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA on new steps to help ensure the quality of and preserve access to com… https://t.co/tz5iQszMlN

RT @FDAfood: The FDA has completed its investigation into a multi-state outbreak of #cyclosporiasis illnesses associated with De… https://t.co/EMKaPwaDP5

My statement on the new steps #FDA is taking to promote access to safe compounded drugs and continue implementation of #DQSA. https://t.co/WmCojrvrkG

The states can play a vital role in reducing the risks associated with compounded drugs, while ensuring appropriate access. In furthering this important partnership and our shared goals, today we've issued a revised draft MOU between #FDA and the states https://t.co/OlSeeA7gor

RT @FDATobacco: The “Tips for Retailers” video has important info on FDA programs and technologies that can assist retailers in pre… https://t.co/K501hom4U3

The revised draft MOU addresses patient access concerns, while retaining critical safety provisions. It is an important step to increase our collaboration with the states to maximize resources and our collective public health impact. https://t.co/OlSeeA7gor

The MOU is a significant milestone in #FDA’s implementation of DQSA. Looking ahead we'll take several more actions on compounding in coming months to promotes safe, appropriate practices https://t.co/OlSeeA7gor I’ll share more on compounding this weekend in #FDA #SUNDAYTWEETORIAL

RT @coukell: Excited that @SGottliebFDA and senior @US_FDA officials will be @pewtrusts next Friday to talk about future efforts… https://t.co/X9W5xm6HjK

RT @FDAOMH: Nicotine, the highly addictive drug in tobacco, keeps people smoking even when they want to quit. During… https://t.co/OTHrFkcUkg

RT @FDACosmetics: DYK The term "cosmeceutical" has no meaning under the law. Don't be confused by cosmetics labeling, find out more… https://t.co/IvPGja6NBj

My recent statement on #FDA’s comprehensive campaign to confront the crisis of opioid abuse and misuse; and some of the new steps that the agency will be taking this fall: https://t.co/v50AHA2yEY

RT @FDASpox: Today, @SGottliebFDA issued a statement on new steps to help ensure the quality of and preserve access to compounde… https://t.co/2qTqGksG4V